OS Therapies Inc. (NASDAQ:OSTX), a pharmaceutical company with a market capitalization of $87.5 million, recently saw a ...

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive Phase 2b top-line data for ...

OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...

Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

Thousands of treated patients support the potential of phage therapy, but limited knowledge of this technique and its ...